Minodronic acid

Minodronic acid

Minodronic acid is a bisphosphonate that was developed and approved for the treatment of osteoporosis in Japan. It is now available in several countries worldwide. It is effective in preventing bone loss, which can help prevent forms of osteoporosis associated with bone loss after oophorectomy in premenopausal women with gynaecologic disease, regardless of age at oophorectomy, cancer type, BMI, or adjuvant therapy.From: Pharmaceutical Biocatalysis [2019], Efficacy of minodronic acid for the prevention of osteoporosis in premenopausal women with gynaecologic disease who undergo bilateral oophorectomy: a single-centre, non-randomised controlled, experimental study [2022]

Synthetic Approaches to Inhibitors of Isoprenoid Biosynthesis

View Chapter

Purchase Book

Published in Peter Grunwald, Pharmaceutical Biocatalysis, 2019

Pedro Merino, Loredana Maiuolo, Ignacio Delso, Vincenzo Algieri, Antonio De Nino, Tomas Tejero

Minodronic acid (202) (Fig. 2.6) was the first bisphosphonate developed and approved for osteoporosis treatment in Japan and today is available in a number of countries worldwide. Minodronic acid 202 and phosphonocarboxylate analog 203.

Efficacy of minodronic acid for the prevention of osteoporosis in premenopausal women with gynaecologic disease who undergo bilateral oophorectomy: a single-centre, non-randomised controlled, experimental study

View Article

Journal Information

Published in Journal of Obstetrics and Gynaecology, 2022

Asumi Okumura, Eiji Kondo, Michiko Kubo-Kaneda, Kenta Yoshida, Tomoaki Ikeda

Minodronic acid have a strong evidence of the treatment for osteoporosis, but has not been shown to be effective as a prophylactic agent. Some previous studies have shown the efficacy of prophylactic minodronic acid administration for osteoporosis prevention after b-OVX in monkeys (Mori et al.2008, Mashiba et al.2017). However, there is no human data of minodronic acid for preventing osteoporosis.

Explore chapters and articles related to this topic

Synthetic Approaches to Inhibitors of Isoprenoid Biosynthesis

Efficacy of minodronic acid for the prevention of osteoporosis in premenopausal women with gynaecologic disease who undergo bilateral oophorectomy: a single-centre, non-randomised controlled, experimental study